Target intelligence / Profile preview

MAGI2 antisense RNA 2 (MAGI2-AS2)

Target
MAGI2-AS2
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Other (non-protein coding RNA)
01

Overview

MAGI2 antisense RNA 2 (MAGI2-AS2) is a long non-coding RNA transcribed antisense to the MAGI2 protein-coding gene on chromosome 7. It functions as a regulatory molecule in post-transcriptional gene expression, modulating cell proliferation, migration, invasion, and oxidative stress by interacting with microRNAs and proteins such as HSPA8. Downregulation of MAGI2-AS2 has been linked to increased tumorigenicity in non-small cell lung cancer and other malignancies, suggesting a tumor-suppressor role. Its mechanisms include miRNA sponging (notably miR-629-5p and miR-31-5p) and protein interactions that affect cell redox status[1][2][4][7]. As a non-protein coding RNA, MAGI2-AS2 is also exemplified as a research focus for therapeutic intervention and biomarker development in oncology.

Other names
MAGI2-AS2MAGI2 antisense RNA 2 (non-protein coding)MAGI2-ASLncMAGI2-AS2 (less common)
02

Mechanism of action

Acts as a competitive endogenous RNA or "miRNA sponge," modulating the activity of microRNAs (e.g., miR-629-5p, miR-31-5p). Regulates downstream tumor suppressor and oncogene pathways (e.g., TXNIP axis). Direct RNA-protein interaction (e.g., HSPA8 binding regulates redox balance).

03

Biological functions

Regulation of gene expression (by antisense interaction and post-transcriptional regulation)Modulates cell proliferationModulates cell migration and invasionTumor suppressor in cancer pathways, including non-small cell lung cancerRNA-protein interactions (e.g., binds HSPA8)
04

Disease associations

Cancer (non-small cell lung cancer, cervical cancer, potentially others)Other diseases (possible broader regulatory effects due to gene expression modulation, but cancer is most documented)
05

Safety considerations

None described. As a nucleic acid target, major therapeutic challenges include delivery specificity, off-target genetic effects, and potential effects on global gene regulation typical of lncRNA-based therapeutics[5].
06

Biomarkers

Low expression levels of MAGI2-AS2 may serve as a biomarker for poor prognosis in certain cancers, such as non-small cell lung cancerChanges in MAGI2-AS2 expression may be used to monitor disease progression or therapeutic response in cancer research.

Beyond the preview

Go deeper on MAGI2 antisense RNA 2 (MAGI2-AS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAGI2 antisense RNA 2 (MAGI2-AS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call